Drug Profile


Alternative Names: MVA-BN-PRO

Latest Information Update: 16 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BN ImmunoTherapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 18 Feb 2013 Interim adverse events and immunogenicity data from a phase I/II trial in Prostate cancer (hormone-refractory, non-metastatic) released by Bavarian Nordic
  • 01 Sep 2011 BN ImmunoTherapeutics completes a phase I trial in Prostate cancer (hormone-refractory, non-metastatic) in USA (NCT00629057)
  • 04 Jun 2008 Phase-I/II clinical trials in Prostate cancer (hormone-refractory, non-metastatic) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top